FDA Recalls – July 6, 2011
You may also be interested in...
Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies, experts tell Medtech Insight.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Blueprint Medicines' Ayvakyt for treating unresectable or metastatic gastrointestinal stromal tumors. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.